Scott Rocklage’s Inventive Knowledge and Prestigious Career in Research Development

In 2003, Scott M. Rocklage PH.D became a Venture Partner with 5AM Ventures and within one year of his tenure, he became Managing Partner. With an astounding knowledge of the health care industry, Scott Rocklage’s role as Managing Partner has paved the way, for advancing life science technologies through bio-pharmaceutical, medical terminology and quantifiable research sectors.

5 AM Ventures operates on a platform of innovating technologies, strategies, development of products with short investment cycles and co-investing with value-based venture capitalists and partners. 5 AM Ventures has also led a wide-variety of numerous clinical trials. The company’s mission is based on maximizing shareholder returns and establishing inherent value.

Through three decades Scott Rocklage has applied a wealth of information and knowledge to bring forth major pharmaceutical improvement’s. His contributions to the medical industry have been profoundly helpful in the areas of medical studies and advancements. Scott Rocklage is responsible, for at least 30 patents with the United States, in which he has either invented, or co-invented and learn more about Scott.

A key role in Scott Rocklage’s contribution has been with regards to cancer treatment. He is responsible, for identifying core elements of specific mutations and genotypes to elevate treatment in the most unique ways possible, for cancer patients. As a researcher, Scott Rocklage has worked alongside some of the world’s most-leading researchers; namely 2005 Nobel Prize winner in Chemistry, Richard R. Schrock. Scott Rocklage received his B.S. in Chemistry from the University of California Berkely. Additionally, Scott Rocklage has received 100-peer reviewed publications worldwide and Scott’s lacrosse camp.

Scott Rocklage’s 30 years in the medical and health care industry has led to promising results such as the food and drug administration (FDA) approval of three essential medical drugs; most recently, omniscan, teslascan, and cubin. He has served as Chairman and CEO of Cubist Pharmaceutical. Additionally, Scott Rocklage holds a position of board member on WaveRx, Pulmatrix and Variation, and the Board of Associates at the Whitehead Institute. Scott Rocklage currently has associations with over 19 scientific, research and medical affiliates.

Scott Rocklage’s highly-respected and well-known research experience is requested by many entrepreneurs, business leaders, leading scientists and physicians, for evaluating medical advancements and risks within the medical industry and more information click here.